Effect of TMS on Neuropathic Pain for Patients With Spinal Cord Injury
Key facts
- Where
- Ankara, TürkiyeSee the 2 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 65 years old?
Source: NCT07293780, who can take part
Where in Türkiye
- Ankara Etlik City HospitalAnkara, TürkiyeContact: Ayşe Naz Kalem ÖzgenTaking people
- Gaziler Physical Therapy and Rehabilitation Training and Research HospitalAnkara, TürkiyeContact: Hatice Ceylan, SpecialistTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Ankara Etlik City Hospital
- Trial code
- NCT07293780
- Record updated
- 2 November 2026
- Original description
Patients will be randomly assigned to three groups using a randomization scheme: active primary motor cortex (M1) rTMS, active anterior cingulate cortex (ACC) rTMS, or sham M1 rTMS. Stimulation will be delivered using a Magstim Rapid2 Magnetic Stimulator (Magstim, Whitland, UK) with figure-of-eight active and sham coils or a double-cone coil, depending on the treatment group. All patients will receive 10 sessions of 5 Hz rTMS over two weeks under physician supervision. Stimulation intensity will be set at 90% of the resting motor threshold (RMT), determined from the contralateral first dorsal interosseous muscle following stimulation of the dominant hemisphere. Each session will consist of 10 trains of stimulation separated by 50-second intervals, delivering a total of 500 pulses. All patients will continue their conventional physical therapy programs throughout the study.Read full original descriptionShow less
The Effect of Transcranial Magnetic Stimulation Applied to the Primary Motor Cortex and Anterior Cingulate Cortex on Refractory Neuropathic Pain in Spinal Cord Injury
Patients will be randomly assigned to three groups using a randomization scheme: active primary motor cortex (M1) rTMS, active anterior cingulate cortex (ACC) rTMS, or sham M1 rTMS. Stimulation will be delivered using a Magstim Rapid2 Magnetic Stimulator (Magstim, Whitland, UK) with figure-of-eight active and sham coils or a double-cone coil, depending on the treatment group. All patients will receive 10 sessions of 5 Hz rTMS over two weeks under physician supervision. Stimulation intensity will be set at 90% of the resting motor threshold (RMT), determined from the contralateral first dorsal interosseous muscle following stimulation of the dominant hemisphere. Each session will consist of 10 trains of stimulation separated by 50-second intervals, delivering a total of 500 pulses. All patients will continue their conventional physical therapy programs throughout the study.
Inclusion: Patients for whom at least 12 months have passed since the date of the spinal cord injury; Patients who meet the International Spinal Cord Injury Pain (ISCIP) Classification criteria for central neuropathic pain below the level of the lesion and who have had pain for at least 6 months; Patients aged 18-65; Pain not attributable to other causes such as rheumatological diseases or diabetes; Patients with VAS > 4 despite maximum dose of pharmacological agents (anticonvulsants, antidepressants, opioids), exercise and physical therapy agents, taking into account renal function tests and other comorbidities.
Exclusion: Metallic implant in the scalp; Cochlear implant; History of epilepsy; Presence of psychiatric illness; Spinal cord stimulator; Pacemaker; Pregnancy.